Considerable evidence suggests that the neurotransmitter γ-aminobutyric acid (GABA)-ergic system and pedunculopontine tegmentum (PPT) in the brainstem are critically involved in the regulation of REM sleep. GABA and its various receptors are normally present in the PPT cholinergic cell compartment. The aim of this study was to identify the role of GABA and its receptors in the regulation of REM sleep. To achieve this aim, specific receptors were activated differentially by local microinjection of selective GABA receptor agonists into the PPT while quantifying its effects on REM sleep in freely moving chronically instrumented rats (n=21). The results demonstrated that when GABA-B receptors were activated by local microinjection of a GABA-B receptor selective agonist, Baclofen, spontaneous REM sleep was suppressed in a dose dependent manner. The optimum dose for REM sleep reduction was 1.5 nmol. In contrast, when GABA-A and GABA-C receptors were activated by microinjecting their receptor selective agonists, Isoguvacine (ISGV) and cis-4-Aminocrotonic acid (CACA) respectively, the total percentages of REM sleep did not change compared to the control values. In another 8 freely moving rats, effects of Baclofen application was tested on firing rates of REM-on cells (n=12). Of those 12 neurons, eleven stopped firing immediately after application of Baclofen (latency: 50 ± 14 sec) and remained almost silent for 130 ± 12 min. Findings of the present study provide direct evidence that the PPT GABA-B receptors and REM-on cells are involved in the regulation of REM sleep. 
INTRODUCTION
The pedunculo pontine tegmentum (PPT), situated in the dorsolateral mesopontine tegmentum, contains a prominent group of cholinergic neurons, which project widely throughout the brainstem and forebrain (for review, see Datta, 1995) . Single cell recordings from the PPT of behaving cats and rats have identified several different classes of cells whose firing rates correlate with both wakefulness and REM sleep (Datta 1995; Datta and Siwek 2002; El-Mansari et al. 1989; Saito et al. 1977; ). Some of these PPT neurons, called REM-on cells, progressively increase their firing rates as the animal moves from wakefulness (W) to slow-wave sleep (SWS) and then to REM sleep (Datta 1995; Datta and Siwek 2002; El-Mansari et al. 1989; Saito et al. 1977; Thakkar et al., 1998) . Others, constituting the majority of these cells in the PPT, called Wake-REM-on cells, are tonically active during both W and REM sleep (Datta 1995; Datta and Siwek 2002) . Microinjection studies in cats and rats have demonstrated that chemical excitation of PPT cells increased both wakefulness and REM sleep by eliminating SWS (Datta and Siwek 1997; Datta et al. 2001a, b) . More recent studies have shown that the activation of PPT kainate receptors induces REM sleep (Datta 2002; Datta et al. 2002) . While activation of PPT NMDA receptors is involved in awake-locomotor activity behavior (Datta et al. 2001b; Garcia-Rill 1991; Garcia-Rill et al. 1990 ).
Neurotransmitter-mediated excitation and inhibition of brainstem cells are important processes for the regulation of wakefulness and REM sleep (Datta 1995; Thakkar et al. 2002) . Recently, considerable progress has been made in identifying the neurotransmitters and receptors involved in the excitation of PPT cells that induce REM sleep (Datta 2002; Datta et al. 2002) . However, the identification of neurotransmitters involved in the inhibition of PPT cells and suppression of REM sleep in freely moving rats and cats remains to be discovered. Based on some indirect studies and on theoretical prediction, it has long been suggested that neurotransmitters like serotonin, norepinephrine, and adenosine are involved in the regulation of REM sleep by inhibiting PPT cell activity (Steriade and McCarley 1990) . On the contrary, one of our recent microinjection studies has demonstrated that the serotonin, norepinephrine, and adenosine in the PPT are not involved in the regulation of REM sleep in the rat (Datta et al. 2003) .
Recently, pharmacological studies have demonstrated that the neurotransmitter GABA is involved in different parts of the brain in the regulation of sleep-wake cycle (Arnaud et al. 2001; Manfridi et al. 2001; Torterolo et al. 2001; Sanford et al. 2003; Xi et al. 1999a, b) . Since the neurotransmitter GABA plays a role in the regulation of sleep-wake cycle and we have shown that the serotonin, norepinephrine, and adenosine may not be involved in the PPT for the regulation of REM sleep (Datta et al. 2003) ; it is likely that GABA is involved in the PPT for the regulation of REM sleep. This proposed role for GABA in the PPT is supported by the fact that the PPT receives GABAergic inputs from the substantia nigra, local neurons, and many other parts of the brain (Beckstead et al. 1979; Carpenter et al. 1981; Jackson and Crossman 1981; Kosaka et al. 1987; Moon-Edley and Graybiel 1983; Mugnaini and Oertel 1985; Scarnati et al. 1988) . In addition to these GABAergic projections, different types of GABA receptors are also present in the PPT (Bowery et al. 1987; Chu et al. 1990 ). The general hypothesis of this study is that the activation of selective GABA receptors in the PPT cholinergic cell compartment inhibits spontaneous REM sleep in freely moving rats.
To identify the specific GABA receptor that has a physiological REM sleep suppressing the effect in freely moving rats, we examined polygraphic wake-sleep signs following microinjections of (1) control vehicle, (2) GABA-A receptor specific agonist, (3) GABA-B receptor specific agonist, and (4) GABA-C receptor specific agonist into the PPT. By comparing the alterations in patterns of REM sleep following injections of control vehicle and selective GABA receptor specific agonists, contributions made by each receptor subtype in REM sleep-suppression were evaluated. In this study, in a limited number of cells, we also examined whether REM sleep suppressing GABA receptor specific agonist suppresses single cell activity of PPT REM-on cell in the freely moving rat.
METHODS

Subjects and Housing
Experiments were performed on 29 male Sprague-Dawley rats (Charles River, Wilmington, MA) weighing between 250 and 350 g each. The rats were housed individually at 24 °C with food and water 5 provided ad libitum with lights on from 07:00 to 19:00 h (light cycle) and off from 19:00 to 07:00 h (dark cycle). Principles for the care and the use of laboratory animals in research, as outlined by the National Institute of Health publication No. 85-23 (1985) , were strictly followed.
Drugs and vehicle for microinjection
The drugs used included GABA-A receptor agonist, Isoguvacine hydrochloride (ISGV; molecular weight: 163.6), GABA-B receptor agonist, Baclofen hydrochloride (Baclofen; molecular weight: 250.13, and GABA-C receptor agonist, cis-4-Aminocrotonic acid (CACA; molecular weight: 101.11). All of these drugs were Sigma-RBI brand (Sigma-Aldrich, Inc., Saint Louis, Missouri, USA). These drugs were dissolved in 0.9% saline. This 0.9% saline was also used for the control vehicle microinjections. Control saline and drug solutions were freshly prepared under sterile conditions before each use. The selection of agonists was based on the selective agonistic effects on specific types of GABA receptors (Bowery 1993; Bowery et al. 1978; Enna and Maggi 1979; Falch et al. 1986; Feigenspan et al. 1993; Fromm et al. 1990; Hill and Bowery 1981; Hong and Henry 1991; Johnston et al. 1975; Kerr and Ong 1995; KrogsgaardLarsen and Johnston 1978; Lukasiewicz and Werblin 1994; Matthews et al. 1994; Misgeld et al. 1995; Paredes and Agmo 1989; Qian and Dowling 1993) . In addition to their selectivity, these drugs are also water soluble and accessible to extracellular receptors.
Surgical procedures and implantation of electrodes
Treatment of the animals and surgical procedures were in accordance with an approved institutional animal welfare protocol . Rats were anesthetized with pentobarbital (40 mg/kg, i.p.), placed in the stereotaxic apparatus, and secured using blunt rodent ear bars. With the use of sterile procedures, cortical electroencephalogram (EEG), dorsal neck muscle electromyogram (EMG), electrooculogram (EOG), and hippocampal EEG (to record theta wave) recording electrodes were chronically implanted in all 29 rats, as described elsewhere (Datta 2001a, b; Datta et al. 2002) . In 21 of these 29 rats, in addition to EEG, EMG, and EOG electrodes, bilateral stainless steel guide tubes (26 gauge) with a fitted stylette of equal length inside were stereotaxically implanted 2 mm above the PPT (A:1.0; L:1.8; H:3.0) (Paxinos and Watson, 1997) as described previously (Datta 2002; Datta et al. 2002) .
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In the remaining 8 rats, in addition to EEG, EMG, and EOG electrodes, one chemitrode (assembly of 12 micro-wires for single cell recording and a guide tube for microinjection) was stereotaxically implanted to microinject saline and Baclofen into the PPT while recording extracellular single cell activities from microinjection site as detailed in our earlier publications (Datta 2002; Datta and Siwek 2002) . Rats were post-surgically treated with buprenorphine (0.2 mg/kg, i.m.) to control any possible pain on recovery from anesthesia.
Habituation and polygraphic recordings
During recovery, habituation, and free moving recording periods, all rats were housed under a 12/12 h light/dark cycle with free access to food and water. Following a post-surgical recovery period of 3-7 days, rats were habituated to a sound attenuated recording cage (size: 2.5 X 1.5 X 1.5 ft) and free moving polygraphic (Grass Polygraph, model #79, Grass Instrument Co., Quincy, MA) and single cell recording conditions for 10 days. All adaptation-recording sessions were performed between 10:00 and 16:00 h, when rats are normally sleeping.
Intracerebral microinjections and experimental design for the identification of the GABA receptor type or types in the PPT that are involved in the regulation of sleep After the adaptation recording sessions were completed, experimental recording sessions were started. During experimental sessions, animals were connected to the polygraphic recording system 15 min before a microinjection into the PPT. The microinjection system and procedures for microinjection in freely moving rats were same as described elsewhere (Datta 2002; Datta et al. 2002; Mavanji and Datta 2003) . Six-hour (between 10:00 and 16:00 h) microinjection recording sessions were begun after a single, unilateral microinjection of 100 nl control saline or one of the four different doses (0.5, 1.0, 1.5, or 3.0 nmol in 100 nl saline) of three different GABA receptor selective agonists (ISGV, Baclofen, and CACA) into the PPT. During microinjection, animals were free to move around the cage with the cannula in place. Due to the extended PE tubing, the injections were made while the animals were moving around. In individual rats, each microinjection was separated by at least 2 days. Each PPT site received no more 7 than three microinjections in three different recording sessions at least 96 h apart. In these three recording sessions, microinjections of control saline or any one of the GABA agonists were never repeated in a single site. The sequence of these microinjections was random. At the end of all experimental sessions and 30 min before perfusion, with the use of the same injector used for GABA agonists and saline, 100 nl of black ink was microinjected to each injection site for histological identification of microinjection sites.
Experimental design to study the effects of Baclofen application on the single cell activity patterns of
REM-on cells
After the adaptation-recording sessions, experimental recording sessions began. During a recording session, each animal was connected to the recording and fluid delivery systems. In the next room, polygraphic signs of the sleep-wake cycle and spontaneous PPT neuronal spikes were continuously monitored on a computer monitor and an oscilloscope and digitized with a computer (between 10:00 and 16:00 h) as described in our earlier publication (Datta and Siwek 2002) . To identify good single cell recording electrode, signals (unitary spike-to-noise >2:1) from each of the micro-wires were recorded for at least two complete sleep-wake cycles as described in our earlier publication (Datta and Siwek 2002) . Once good quality, presumed somatic unitary spike potentials (biphasic or negative >1 ms) were identified, signals from those individual micro-wires were recorded 8 continuously for at least two sleep-waking cycles to positively identify REM-on cell. REM-on cells exhibited increased (>50%) firing discharge in REM sleep compared with W and SWS (Datta 1995; Datta and Siwek 2002) . Normally, the PPT REM-on cells in the rat are almost silent during wakefulness and SWS. The average firing rates are in a range between 0.1 and 0.3 Hz (Datta, 1995; Datta and Siwek, 2002) . Five to 10 sec before the onset of REM sleep, the firing rate of REM-on cells began to increase and reached their maximal rate at the beginning of REM sleep. This firing rate remains high (between 5 and15 Hz) throughout the entire REM sleep episode. Five to 8 sec prior to the REM sleep, their firing rate drops dramatically and the neurons cease firing as soon as the rat enters into wakefulness or SWS. Once a REM-on cell was identified, during SWS, 50-nl volume of Baclofen was slowly (over a 60-s period) microinjected into the recording site. After microinjection of Baclofen, polygraphic signs and single cell activity were recorded until those cells began to fire in a normal state-dependent manner (like before microinjection of Baclofen). Following this recovery, the injector cannula was replaced with a same size injector cannula filled with saline. Again, when the animal entered into the SWS state, 50-nl volume of saline was microinjected into the same site where Baclofen was microinjected. After microinjection of saline, single cell activity and polygraphic recordings were continued for at least one complete sleepwake cycle. At the end of all recording sessions and 30 min before perfusion, 100 nl of black ink was microinjected into each injection site for localizing microinjection sites.
Unitary spikes and square-wave pulses triggered by well-discriminated unit action potentials (via window discriminator), as well as polygraphic signals of polygraphic sleep-wake signs were stored in a computer for subsequent off-line analyses. Amplified original single cell recording signals were also recorded on a digital tape recorder (DTR) for off-line computerized analysis using "Experimenters Work Bench" software (DataWave Technologies, Longmont, CO).
Histological localization of single cell recording and microinjection site
At the conclusion of all recoding sessions, rats were deeply anesthetized with pentobarbital (60 mg/kg, i.p.) and perfused transcardially with heparinized cold phosphate buffer (0.1 M, pH 7.4) followed by 4% paraformaldehyde in 0.1 M phosphate buffer. The brains were removed and processed for NADPH-diaphorase staining and histological localization of single cell recording and microinjection sites as described earlier (Datta and Hobson 1994; Datta and Siwek 2002; Datta et al. 2001a, b) .
Scoring of behavioral states and analysis of neuronal activity
Polygraphic data were scored visually for W, SWS, and REM sleep as described in our earlier publications (Datta 2000 (Datta , 2002 Datta and Siwek 2002) . Action potentials were collected from the DTR via a DataWave acquisition system and stored in the computer with proper labeling of cell number and behavioral state. These stored action potentials were first discriminated on the basis of their height, duration, and shape to make sure that they were from the same cell body before they were subjected to further analysis. The discriminated unitary action potentials were analyzed to determine firing rate with the use of the "Experimenters Work Bench" software of the Data Wave System as described earlier (Datta and Hobson 1994; Datta and Siwek 2002) . The mean firing rate (in Hz) for each cell was computed separately during the epochs of W, SWS, and REM sleep. Paired t-tests were used to calculate statistical differences in firing rate between before microinjection of Baclofen and after microinjection of saline during W, SWS, and REM sleep.
Statistical analyses
For the purposes of determining possible effects on sleep and wakefulness, three behavioral states were distinguished based on the visual scoring of polygraphic records as described earlier (Datta 2000 (Datta , 2002 Datta and Siwek 2002) . The behavioral states of W, SWS, and REM sleep were scored in successive 10 sec epochs. The polygraphic measures provided the following dependent variables that are quantified for each trial: 1. Percentage of recording time spent in W, SWS, and REM sleep; 2. Latencies to the onset of the first episode of REM sleep after the onset of injection; 3. Total number of REM sleep episodes in 6 h recording session; 4. Mean duration of REM sleep episodes in 6 h recording session. To identify the type of GABA receptor that could be involved in the regulation of sleep, the effects of the 13 different treatments (saline; 3 agonist X 4 doses = 12 drug treatment groups) on the total percentages of W, SWS, and REM sleep were statistically analyzed using one factor ANOVA. For detailed analysis of Baclofen effects, the effects of the five different treatments (saline, 0.5 nmol Baclofen, 1.0 nmol Baclofen, 1.5 nmol Baclofen and 3.0 nmol Baclofen) on the percentages of W, SWS, and REM sleep were statistically analyzed using a two-way ANOVA with time as a repeated measure within subject variable (6 levels corresponding to 6 one hour epochs following injections) and treatment as a betweensubject variable (5 levels corresponding to the 5 different treatments). Following a two-way ANOVA, post hoc Scheffe F tests were done to determine the individual levels of significant difference between control (saline) and the four different Baclofen doses at six individual data points. Statistical analyses (One factor ANOVA, two-way ANOVA, Scheffe F-test) were performed with the use of StatView statistical software (Abacus Concepts, Berkeley, CA). Figure 1) Effects of three different GABA receptor specific agonists microinjection into the PPT on wakefulness and sleep
RESULTS (Insert
Immediately following microinjection of all four different doses of Baclofen, animals assumed a lying down position in one corner of the recording chamber. Although, we did not quantify any individual waking behavior (like, exploratory, grooming, feeding, and drinking behaviors), based on our qualitative observation, after Baclofen microinjection, the animals' normal active behaviors were minimal compared to those following microinjections of saline control, ISGV, or CACA. These behavioral observations indicated that the Baclofen microinjections into the PPT induce pre-somnic behavior in the rat.
To identify the GABA receptor type or types in the PPT that are involved in the regulation of (Fig. 4) . During the sixth hour, REM sleep percentages of both doses returned to their saline control level. Comparison between the 1.5 and 3.0 mol doses of Baclofen suggests that the 1.5 mol dose of Baclofen is optimum for the maximum change of REM sleep. Figure 5) 
(Insert
Effects of Baclofen application on the single cell activity patterns of REM-on cells
Having documented that the Baclofen microinjection into the PPT suppress REM sleep, we next tested the effect of Baclofen on spontaneous unitary activity in 12 REM-on cells in the PPT. Figure 5 illustrates single cell activity patterns of a typical PPT REM-on cell before and after diffusion of 7.15 ± 1.9 Hz) between before and after microinjection of saline in the recording site. These results indicate that the application of Baclofen caused PPT REM-on cells to reduce firing.
DISCUSSION
The principal findings of this study are that (1) microinjections of GABA-B receptor selective agonist, Baclofen, into the PPT decreases REM sleep in a dose-dependent manner, (2) Baclofen suppresses extracellular unitary activity of PPT REM-on cells, (3) Baclofen microinjection into the PPT also reduces the total amount of wakefulness in a dose-dependent manner, and (4) microinjections of GABA-A and GABA-C receptors selective agonists, ISGV and CACA, into the PPT do not change 15 wakefulness or sleep parameters. As a consequence of the Baclofen-induced decrease in wakefulness and REM sleep, slow-wave sleep is increased. The results presented here strengthen and extend hypothesis that neurotransmitter-mediated activation and inhibition of the cholinergic cell compartment of the PPT are critical processes for regulating wakefulness and REM sleep (Datta 1995) . The findings are discussed in relation to ongoing efforts to understand the mechanisms by which activation and inhibition of the PPT contributes to the regulation of REM sleep.
A major limitation of the microinjection method relates to the diversity in the neurochemical nature of the neuronal population affected by the drug application. In the present study, all of our microinjection as well as single cell recording sites were in the middle of the NADPH-diaphorase-positive cell compartment of the PPT. In the rat, this part of the PPT is called pars compacta, where most cells are known to be cholinergic (Mesulam et al. 1983; Datta, 1995) . These cholinergic cells are also capable of synthesizing nitric oxide (Datta, 1995) . Since, the spike durations and firing rates of these REM-on cells were similar to those of identified cholinergic cells in the PPT and LDT (Datta and Siwek, 2002; Kayama et al. 1992) ; it is likely that the phenotype of those REM-on cells recorded in this study were also cholinergic. In the cat, some PPT cells, especially those in the caudal part of the PPT, were also shown to be aminergic (Datta, 1995) . A recent immunohistochemical study in the cat showed that 50% of the PPT cholinergic cells also contain GABA (Jia et al. 2003) . Thus, it is clear that each of these PPT cells is capable of synthesizing more than one neurotransmitter. We acknowledge that if there are non-cholinergic cells located within these cholinergic cell groups they will be also affected by the application of GABAergic drugs. Another limitation, which can be confirmed and extended by future studies, is to identify the role of endogenous GABA and its specific receptors in the PPT in the regulation of spontaneous REM sleep. In this study, we chose specific agonists to activate different GABA receptors to identify the involvement of each GABA receptor in the suppression of REM sleep. The use of agonists permitted identification of the consequences of activation of a particular receptor type in a restricted brain region in the modulation of REM sleep. The present results point to the need for future studies using GABA receptor specific antagonists to confirm the receptor specificity of the present study and to identify the role of endogenous GABA and its specific receptors in the PPT in the regulation of physiological REM sleep.
In the last five years, evidence has accumulated indicating that the neurotransmitter glutamate is the excitatory input for the activation of PPT cells and induction of both wakefulness and REM sleep (Datta and Siwek 1997; Datta et al. 2001a, b) . Most importantly, those studies have demonstrated that the tonic activation of PPT kainate receptors induces REM sleep and activation of PPT NMDA receptors induces wakefulness (Datta 2002; Datta et al. 2001b Datta et al. , 2002 . Since neurotransmitter-mediated excitation and inhibition of PPT cells have been suggested to be important processes for the regulation of wakefulness and REM sleep, we began our examination to identify neurotransmitters and their receptors that may be involved in the inhibition of PPT cells and REM sleep. On that quest, we have shown in our earlier study that serotonin, norepinephrine, and adenosine may not be involved in the PPT for the regulation of REM sleep (Datta et al. 2003) . Recent pharmacological and immuno-histochemical studies have shown that the GABAergic system in the brainstem (caudal and rostral parts of the nucleus pontis reticularis) is involved in the modulation of wakefulness and REM sleep (Sanford et al. 2003; Torterolo et al. 2001; Xi et al. 1999a Xi et al. , b, 2001 . Since the PPT receives inhibitory GABAergic inputs from the substantia nigra, local neurons, and many other parts of the brain (Beckstead 1982; Carpenter et al. 1981; Jackson and Crossman 1981; Jia et al. 2003; MoonEdley and Graybiel 1983; Reese et al. 1995; Scarnati and Florio 1997; Scarnati et al. 1988; Steininger et al. 1992) , PPT cell activity may also be modulated by GABAergic neurotransmission. The possibility that GABAergic neurotransmission in the PPT may modulate PPT cell activity is also supported by the fact that different types of GABA receptors and GABAergic fibers are present in the PPT (Bowery et al. 1987; Chu et al. 1990; Kosaka et al. 1987; Mugnaini and Oertel 1985) . Consistent with the suggestion that the GABAergic system could modulate the activity of PPT cells, the results of the present study provide the first direct evidence that the activation of GABA-B receptors within the PPT causes suppression of REM sleep, partly by inhibiting the extracellular activity of the REM-on cell. In addition to the suppression of REM sleep, our results demonstrated that the activation of GABA-B receptors in the PPT reduces the total percentages of wakefulness. This interpretation is also supported by another intra-cerebro-ventricular (i.c.v.) injection study that has shown that the application of GABA-B receptor antagonist increases wakefulness and REM sleep in the rat (Gauthier et al. 1997 ).
Since, we are mainly focusing on the regulation of REM sleep, in this study we did not study the effects of Baclofen microinjection on the extracellular activities of Wake-REM-on or Wake-on cells.
Based on the behavioral effects of Baclofen microinjection, it is expected that the application of Baclofen would also inhibit Wake-REM-on and Wake-on cells. This anticipated result would suggest that the GABA-B receptors in the PPT are also involved in the modulation/regulation of wakefulness. In this respect, the major function of the GABA-B receptors in the PPT cholinergic cell compartment of the PPT is to suppress wakefulness. Besides\ the results of this study, there are two other lines of evidence implicating involvement of the PPT cholinergic cells in wakefulness. The first comes from extracellular single-cell recording studies. One group of PPT cholinergic cells is active both during wakefulness and REM sleep (Datta, 1995; Datta and Siwek, 2002; El-Mansari et al. 1989 ). These cells have a much higher firing rate during W than during REM sleep (Datta and Siwek, 2002) . The second line of evidence comes from the receptor activation studies. Activation of post-synaptic NMDA receptors in the cholinergic cell compartment of the PPT induces locomotor activity, wakefulness and cortical activation (Datta et al. 2001b; Datta and Siwek, 1997; Garcia-Rill et al. 1990 ). To better understand the mechanisms of Baclofen-induced and/or GABA-B receptor-induced reduction of wakefulness, future studies may require to examine the effects of Baclofen on the extracellular activities of Wake-REM-on and Wake-on cells of the PPT.
In the present study, microinjections of GABA-A or GABA-C receptor agonist into the PPT did not produce any significant changes in the wakefulness and/or sleep. These results indicate that the GABA-A and GABA-C receptors in the PPT may not be involved in the modulation of wakefulness and sleep. Indeed, another study in the freely moving cat has shown that the GABA-A receptor antagonist, bicuculline, microinjection into the PPT does not have any significant effect on wakefulness and sleep (Sanford et al. 1998) . It is interesting to note that application of GABA-A receptor agonist and antagonists were effective in changing REM sleep in the both cats and rodents when they were applied into the nucleus pontis reticularis (Pollack and Mistlberger 2003; Sanford et al. 2003; Torterolo et al. 18 2001; Xi et al. 1999a Xi et al. , b, 2001 , where carbachol microinjections induce REM sleep (Shiromani and McGinty, 1986; Bourgin et al. 1995; Datta, 1995; Marks and Birabil 1998, 2001 ). All of these GABAergic receptor manipulation studies have shown that activation of the GABA-A receptor in the nucleus pontis reticularis, by application of GABA-A receptor agonist, suppresses REM sleep.
Conversely, the application of GABA-A receptor selective antagonist, increase REM sleep. The lack of effect of GABA-A receptor agonist on REM sleep, when microinjected into the PPT, compared with the REM sleep suppressing effect of GABA-A receptor agonist, when microinjected into the nucleus pontis reticularis, indicates that there may be a considerable regional specificity for different types of GABA receptors involved in the regulation of REM sleep. In summary, activation of both GABA-A receptors in the nucleus pontis reticularis and GABA-B receptors in the PPT suppresses REM sleep. Although, there is no comparable study using GABA-C receptor manipulation in the PPT and/or nucleus pontis reticularis; nonetheless, one study in the rat has shown that the intra-cerebro-ventricular (i.c.v.) injection of GABA-C receptor antagonist increase wakefulness and decrease both SWS and REM sleep (Arnaud et al. 2001) . Since, we have demonstrated that activation of GABA-C receptors in the PPT does not cause any changes in the wakefulness and/or sleep, it is likely that the i.c.v. injection of GABA-C antagonist might have acted yet in another site to induce its effects on the wakefulness and sleep.
In conclusion, the present study shows for the first time that activation of GABA-B receptors in the PPT is a critical step for the regulation of REM sleep. The data provide a novel perspective on the regulatory aspect of PPT cells' activity in the regulation of REM sleep. The results also suggest that the different REM sleep regulatory sites in the brain may use different types of GABA receptors for the regulation of REM sleep. 
